Skip to main content
Journal cover image

Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events.

Publication ,  Journal Article
Monuszko, KA; Fish, LJ; Sparacio, D; Lizaso, C; Burn, K; Wickenheisser, NE; Meyer, LA; Reed, SD; Davidson, BA; Havrilesky, LJ
Published in: Gynecol Oncol Rep
October 2022

OBJECTIVE: The online environment is an ideal setting to understand how many women seek, receive, and understand information about cancer treatment. The purpose of this study was to understand women's needs and information-seeking around Poly ADP ribose polymerase (PARP) inhibitors, an oral medication commonly prescribed as maintenance therapy at the conclusion of primary chemotherapy for ovarian cancer. METHODS: We held online discussion events with two social media communities, #gyncsm social media on Twitter and the Smart Patients ovarian cancer community, in November 2020, to sample ovarian cancer patient perceptions of, and information seeking about PARP inhibitors. Focused questions were presented to both communities, with participants able to answer and elaborate upon these questions, as well as to add their own comments or topics. Qualitative content analysis was performed on the transcripts from the two online events. RESULTS: A total of 254 unique tweets and 71 messages were generated from the Twitter and Smart Patients conversations, respectively. The majority of the content from these two events could be categorized into five major themes: (1) concerns about side effects, (2) expectations of benefit, (3) desire for more information regarding clinical trials, ) (4) desire to better understand the relationship between mutation status and PARP inhibitor effectiveness, and (5) financial toxicity. Misinformation was rarely identified. CONCLUSIONS: Women with ovarian cancer who are engaged in online patient communities have numerous educational needs regarding PARP inhibitors. Given the complexity of clinical research on PARP inhibitors, patients would likely benefit from patient-centered educational tools.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol Rep

DOI

ISSN

2352-5789

Publication Date

October 2022

Volume

43

Start / End Page

101050

Location

Netherlands
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Monuszko, K. A., Fish, L. J., Sparacio, D., Lizaso, C., Burn, K., Wickenheisser, N. E., … Havrilesky, L. J. (2022). Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events. Gynecol Oncol Rep, 43, 101050. https://doi.org/10.1016/j.gore.2022.101050
Monuszko, Karen A., Laura J. Fish, Dorinda Sparacio, Christina Lizaso, Kathryn Burn, Natalie E. Wickenheisser, Larissa A. Meyer, Shelby D. Reed, Brittany A. Davidson, and Laura J. Havrilesky. “Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events.Gynecol Oncol Rep 43 (October 2022): 101050. https://doi.org/10.1016/j.gore.2022.101050.
Monuszko KA, Fish LJ, Sparacio D, Lizaso C, Burn K, Wickenheisser NE, et al. Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events. Gynecol Oncol Rep. 2022 Oct;43:101050.
Monuszko, Karen A., et al. “Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events.Gynecol Oncol Rep, vol. 43, Oct. 2022, p. 101050. Pubmed, doi:10.1016/j.gore.2022.101050.
Monuszko KA, Fish LJ, Sparacio D, Lizaso C, Burn K, Wickenheisser NE, Meyer LA, Reed SD, Davidson BA, Havrilesky LJ. Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events. Gynecol Oncol Rep. 2022 Oct;43:101050.
Journal cover image

Published In

Gynecol Oncol Rep

DOI

ISSN

2352-5789

Publication Date

October 2022

Volume

43

Start / End Page

101050

Location

Netherlands